FDA RPD Designation Granted for RC220 Bisantrene
Released
Latest announcements
Announcement summary
FDA RPD Designation Granted for RC220 Bisantrene
We invite investors to post their questions, comments and feedback on the 'ask a question' section on this page.
Ask a question
Your question will be sent privately to Racura Oncology. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Racura Oncology a question about this announcement.